The Weekly Checkup: Week of May 4-8, 2026

Issue #5 | Week of May 4-8, 2026

62 announced transactions this week, a big increase from last week's 50, and the composition shifted meaningfully with the growth coming on the healthcare services side: Services 42, Technology 20, with 9 platform deals. That platform count is the highest so far, and I expect it to mostly improve going forward. The strategics are active, the platforms are doing add-ons… and the new platform investments should continue to come.

Cross Country Healthcare finally has a buyer after a messy year involving a cancelled Aya Healthcare merger, an FTC second request, and a goodwill impairment. The deal is an interesting datapoint for everyone tracking travel nurse staffing: the current EBITDA multiple is high, but these are trough levels, and the fairness opinion from the failed Aya deal tells a story about management projections that did not age well. Global Medical Response launched its IPO this week, targeting up to $5 billion in equity value on a business that has $5 billion in debt and adjusted FY 2025 EBITDA of $1.19 billion. Addus HomeCare entered Indiana with the HomeCourt acquisition and immediately announced a second deal in the same state, which is a common market-entry sequencing pattern in private duty. BrightSpring reported Q1 results showing its Amedisys/LHC asset acquisition contributed $79 million in revenue and $9 million in EBITDA in a single quarter.

I was hoping to get to the Talkspace and Select Medical fairness opinions this week, but we just don’t have the space this time. Hopefully next week.

Deal value: $437 million | EV / Revenue: 0.41x | EV / EBITDA: 16.3x

Knox Lane announced the all-cash acquisition of Cross Country Healthcare for $13.25 per share. The 31% premium to the prior close and 45% premium to the 90-day VWAP sound impressive until you remember that Cross Country spent much of 2025 trading at depressed levels following the collapse of its Aya Healthcare merger, during which it paid Aya a $20 million termination fee and took a $77.9 million goodwill impairment charge. The company generated FY 2025 revenue of $1.054 billion and adjusted EBITDA of $26.8 million, just a 2.5% margin.

My take: The EBITDA multiple of 16.3x on a 2.5% margin business looks great: but it's not that Knox Lane paid a rich EBITDA multiple, it's that Cross Country's EBITDA is depressed relative to what a normalized staffing business should earn. The revenue multiple of 0.41x for a travel nurse staffing business of this scale is not high. The Aya Healthcare fairness opinion filed with the SEC in early 2025 showed management projections that assumed a material revenue and EBITDA recovery in 2025 and 2026 ($1.27b revenue, $53m adjusted EBITDA). Those projections have, to put it charitably, not materialized. Full-year 2025 revenue of $1.054 billion came in well below what the fairness opinion models contemplated, and EBITDA margin of 2.5% is a fraction of what management projected. The lesson for buyers and sellers valuing staffing businesses on projected recovery earnings: when a category has been correcting for two-plus years, management projections for recovery tend to be optimistic, and buyers who pay on those projections risk overpaying. It doesn’t look like Knox Lane is paying on the same projections, though, and the 0.41x revenue multiple gives them meaningful upside if the travel nurse market recovers. A rebound in travel nurse demand is bound to happen, but it seems like the consensus has been 'next year' for three years running… which means next year, right?

Deal value: $12.5 million | EV / Revenue: 1.28x

Addus HomeCare announced the acquisition of HomeCourt Home Care, an Indiana-based personal care provider serving approximately 240 clients and generating approximately $9.8 million in annual revenue. On the same Q1 earnings call, Addus disclosed a second definitive purchase agreement for a similarly sized Indiana provider expected to close in the coming months. The company has been eyeing Indiana for three years due to the state's rate increases and efforts to eliminate client waitlists.

My take: The 1.28x revenue multiple on HomeCourt is consistent with the high end of where Addus has historically priced non-medical tuck-ins. A look at the Scope database shows Addus has completed roughly a dozen personal care acquisitions since 2017 at revenue multiples ranging from 0.38x to 1.26x, depending on market, payer mix, and size, with more recent transactions trending toward the higher end of that range as Indiana and other expansion markets have seen rate improvement. What stands out here is the sequencing: Addus announced the HomeCourt deal and a second Indiana deal in the same earnings call, the same "batch close" behavior we flagged with Bridge Dental and Southern Orthodontic Partners in Issues #1 and #2, and with Playground Pediatrics' four-practice same-day announcement in Issue #4. For personal care providers in Indiana and adjacent markets: the state's improving rate environment and waitlist reduction programs are making it a priority market for the large publicly traded personal care platforms. If you operate a profitable personal care book in Indiana, Ohio, or neighboring states, the buyer pool is deeper today than it was 18 months ago, and Addus is not the only name in the market.

GMR Solutions, the KKR-backed emergency medical services company operating as Global Medical Response, launched its IPO this week seeking to raise up to $797.9 million by offering 31.9 million shares at $22 to $25 per share. The company operates approximately 7,400 ground ambulances and 515 air ambulances across 45 states.

My take: The implied multiple math is worth working through explicitly, because the $5 billion equity figure does not tell the full story. According to the S-1, GMR carries $5.05 billion in debt as of December 31, 2025. At a $5 billion equity valuation, the implied enterprise value is approximately $10 billion. GMR generated $5.74 billion in revenue and $1.19 billion in adjusted EBITDA in 2025. That puts the implied EV/EBITDA at approximately 8.4x and EV/Revenue at approximately 1.74x. For reference, our ambulance transaction database shows historical ground ambulance transactions ranging from 5.2x to 11.2x EBITDA and air ambulance transactions at 6.1x to 7.6x. An 8.4x blended multiple on a business of this scale, with the country's dominant ground and air EMS footprint, is not expensive in the context of those comps. What is notable is the leverage: $5 billion of debt against $1.19 billion of EBITDA implies a debt-to-EBITDA ratio of approximately 4.2x at closing. KKR is clearly using the IPO proceeds, along with the $350 million of private placement warrants from KKR, Ares, and HPS, primarily to delever. The IPO is a balance sheet event more than an operational one. For anyone valuing ground or air ambulance assets right now, GMR's implied metrics at offering are a useful reference point for enterprise-level comps in a category where public benchmarks are rare.

Roche announced the acquisition of PathAI, a Boston-based company in digital pathology and AI-powered diagnostics. The deal includes $750 million upfront and up to $300 million in milestone payments, for a total potential value of $1.05 billion. PathAI has been partnered with Roche since 2021 and expanded that partnership in 2024 to include AI-enabled companion diagnostic algorithms.

My take: The structure here is the teaching point. $750 million certain upfront plus $300 million in milestones tied to presumably regulatory and commercial outcomes is a template that has become common in AI-enabled diagnostics and life sciences software: the buyer prices the current platform and validated pipeline at one number, and the seller retains participation in upside from events that are not yet de-risked. For sellers and their advisors in digital pathology, computational biology, and AI diagnostics, the Roche/PathAI deal provides a useful framework: existing strategic partnership plus de-risked algorithm performance plus companion diagnostic validation potential equals structurable premium to a standalone DCF. The milestone structure also allows Roche to cap its downside if the algorithms do not achieve the regulatory outcomes they are targeting. Neither side gets exactly what they would have in a pure cash deal, and that is usually how the best-structured transactions in uncertain categories close.

Carlyle announced the simultaneous acquisition of Knack RCM and EqualizeRCM, two complementary healthcare revenue cycle management providers, to create what it describes as an AI-native, global, multi-specialty RCM platform. Together the companies cover DME, anesthesia, eye care, behavioral health, rural hospitals, urgent care, and multi-specialty physician groups.

My take: The dual-acquisition structure is worth noting. Carlyle is not building this platform incrementally: they bought the complementary specialty coverage in a single transaction, which compresses the time to market for a product they can sell to health systems and physician groups as a multi-specialty solution. This is the same logic CPIhealth used when it acquired the physician practice and ASC on the same day in Issue #2, just applied to the vendor side. For RCM companies with specialty concentration in categories Knack and Equalize do not cover well, including home health, hospice, and certain payer-specific workflows, the Carlyle platform's appetite for specialty add-ons should be high. The broader observation: AI-native branding in RCM is helping to justify platform-level multiples, and buyers who can credibly demonstrate automation-driven margin improvement are getting the benefit of the doubt from financial sponsors.

Amulet Capital Partners acquired TFP Fertility Group, one of the leading fertility care providers in the UK and Northern Europe, from Benefit Street Partners. TFP operates 10 fertility clinics and 21 satellite/referral centers across the UK and Poland.

My take: Fertility continues to attract dedicated financial sponsor attention despite the clinical complexity and regulatory variation across European markets. The UK fertility market operates under a specific regulatory framework through the HFEA, and the Polish market has a different payer and legal structure, which means this is not a simple multi-site operator: it is a multi-jurisdiction regulatory asset. For US-based advisors and investors tracking fertility consolidation, the European comp set is useful context: TFP's exit from Benefit Street is a secondary PE transaction, meaning the multiple paid reflects what financial sponsors think the platform can earn under continued active ownership. Pinnacle Fertility's addition of Genesis Fertility in New York this week, also in the volume, signals that the fertility consolidation story is equally active on this side of the Atlantic.

I tracked 50 additional transactions this week, including notable activity in behavioral health (KidsPeace / Inperium, TimelyCare / Alongside), hospital consolidation (WakeMed / Atrium Health, UPMC / Trinity Health System Ohio), life sciences data (HealthVerity / Symphony Health), and pharma (Bayer / Perfuse Therapeutics, UCB / Candid Therapeutics).

Deal value: $238.5 million (100% EV) | EV / Revenue: 0.69x | EV / EBITDA: 7.95x (Year 1 projection)

Vault deals pull something from the Scope database and walks through the underlying documents in more detail. The goal is to show the kind of detail we surface on the roughly 2,900+ healthcare transactions in our valuation database, and to give subscribers a more useful comparable they can act on.

This week I’m covering BrightSpring's acquisition of home health and hospice branches divested by Amedisys and LHC Group as a condition of their merger with Optum. The regulatory divestiture was announced in May of 2025 and close December 1st.

What the press release said: BrightSpring paid $238.5 million for the divested branches, which were expected to generate $345 million in annualized revenue. The company was silent on margins or EBITDA until now, disclosing that the acquired assets would drive approximately $30 million in EBITDA in year one, implying a year-one EBITDA multiple of approximately 7.95x and a revenue multiple of 0.69x. BrightSpring described the opportunity as having "unbelievable runway" given the fragmented nature of home health in the markets where the branches operate.

What the post-close earnings data added: Q1 2026 is the first quarter with a full contribution from the acquired branches, and BrightSpring disclosed the actual contribution on its May 1 earnings call: $79 million in revenue and approximately $9 million in adjusted EBITDA for the quarter. Annualizing those figures produces approximately $316 million in revenue and $36 million in EBITDA, which implies a year-one EBITDA run rate slightly ahead of the $30 million projection and a revenue run rate modestly below the $345 million projection.

Why it matters: Regulatory divestitures, where branches are carved out as a condition of a larger merger approval, typically trade at a discount to whole-company comps because of integration complexity, operational disruption during the transition period, and uncertainty about whether the acquired branches can maintain their referral relationships under new ownership. The 0.69x revenue multiple on these assets reflects that discount. BrightSpring's Q1 performance suggests the integration has gone better than expected in the early going, and the EBITDA trajectory is tracking ahead of plan. For anyone valuing home health assets of this size in secondary markets: the 7.95x year-one EBITDA multiple on a carve-out from a regulatory divestiture is a meaningful lower bound. Arm's-length whole-company transactions in similar markets are trading higher.

Scope Research's valuation database has approximately 2,900+ healthcare M&A transactions with disclosed or derived revenue and EBITDA multiples going back to 2010. The underlying source documents, including cost reports, CON filings, bond disclosures, and audited financials, are what make those figures reliable.

Location: Massachusetts | Asking Price: $11.9M | Revenue: $6.4M | Cash Flow: $2.4M | CF Margin: 37.5% | Price / Revenue: 1.86x | Price / Cash Flow: 4.96x

Combined healthcare staffing and medical transportation business based in Massachusetts. The 37.5% cash flow margin is unusually strong for a staffing business, which suggests the transportation component may be driving disproportionate economics, but the description is incredibly vague.

My take: The first question for any serious buyer here is how these two revenue streams are legally and operationally structured, because they have completely different regulatory profiles. Healthcare staffing in Massachusetts is subject to standard labor and credentialing requirements. Medical transportation in Massachusetts, depending on whether it involves emergency or non-emergency services, implicates DPH licensure, Medicaid NEMT contracts, and potentially MassHealth billing requirements - as does the brief mention of home care and hospice in the description. The vague description, broad services, and high margins warrant scrutiny: true staffing businesses rarely produce margins above 15-20% at this revenue scale… hinting at either a favorable payer mix or out-of-network pricing model in the transportation segment, significant owner involvement that has not been accounted for, or contractual structures that may not be fully transferable. The 1.86x revenue multiple is above where most businesses in these segments trade, but Massachusetts is one of the more attractive markets in the country for businesses that rely on Medicaid funded programs as a primary payer. A qualified buyer should demand a detailed revenue and margin bridge by service line before moving forward on the asking price.

Location: Arizona | Asking Price: $8.3M | Revenue: $15.4M | Cash Flow: $2.85M | CF Margin: 18.6% | Price / Revenue: 0.54x | Price / Cash Flow: 2.93x

An established healthcare staffing operation being sold as a line of business by a general staffing company exiting the healthcare business to focus on its core operations. The business has filled thousands of temporary, permanent, and locum tenens positions over 20 years. Gross margin is 40.1%. 90-95% of business comes from referrals and repeat business.

My take: Buying a "line of business" rather than a standalone company is a structure that requires careful legal and operational diligence that is often underweighted by acquirers. The key question is what transfers and what does not: specifically, are the client contracts assignable, does the seller maintain a non-compete in the acquired specialties and geographies, and does the referral-driven revenue actually follow the book or the seller's relationships? The 0.54x revenue multiple is pretty cheap in isolation, particularly in light of the reported margins, and likely reflects both the structural uncertainty of a line-of-business sale and the broader headwinds in healthcare staffing. The 40.1% gross margin is legitimately strong and suggests a favorable specialty mix, likely physician and advanced practitioner placements, where the market has reportedly started growing again. With several years of staffing sector normalization still underway, this requires a buyer who can comfortably underwrite to current volumes, not projected recovery, and model conservatively on client contract retention.

Location: Ohio | Asking Price: $5.7M | Revenue: $18.0M | Cash Flow: $1.5M | CF Margin: 8.3% | Price / Revenue: 0.32x | Price / Cash Flow: 3.80x

NEMT provider completing nearly 640,000 trips annually, with over 90% of revenue from government-subsidized contracts. The business has operated for nearly 100 years (originally a taxi service that pivoted to NEMT approximately 20 years ago) and dominates its local market. 180 employees. Owners seeking retirement.

My take: The 8.3% cash flow margin on a government-contract NEMT business is consistent with the industry, where Medicaid brokerage contract structures compress margins and volume is everything. The 0.32x revenue multiple looks very cheap and is worth interrogating: at this revenue level, a buyer should expect to pay closer to 0.4-0.6x revenue for a business with dominant local market share, assuming the government contracts are long-term, assignable, and not subject to rebid in the near term. The most important diligence question here is contract transferability: Ohio Medicaid transportation contracts typically require state approval for change of ownership, and the timeline for that process can meaningfully affect closing economics and deal structure. A buyer who does not understand the CHOW process for NEMT in Ohio should engage an Ohio-specific healthcare regulatory advisor before proceeding. The 640,000 annual trips is a meaningful operational scale, and a strategic acquirer with existing NEMT infrastructure could rationalize this acquisition at the ask and then some.

Location: Suffolk County, NY | Asking Price: $3.9M | Revenue: $3.9M | Cash Flow: $600K | CF Margin: 15.4% | Price / Revenue: 1.0x | Price / Cash Flow: 6.5x

26-year-old NEMT business in Suffolk County with a fleet of 34 vehicles, 28 drivers, and a complete management team. Seller financing available at $1.2M down, balance over 24 months at 7%.

My take: The 6.5x cash flow multiple on a New York NEMT business looks steep relative to the Ohio listing above, but it reflects a few things that deserve credit: Suffolk County is a high-acuity market with a strong Medicaid population and higher per-trip reimbursement than most Ohio markets, 26 years of operating history suggests durable contract relationships, and the seller's willingness to finance 70% of the purchase price suggests confidence in forward cash flows. The central diligence priority is New York State TLC and DOH licensure: New York vehicle-for-hire and NEMT regulation is layered, and license transferability on a change of ownership is not automatic. Any buyer should run a full regulatory review on the existing licenses before negotiating final price. The 15.4% cash flow margin is above the 8.3% seen in the Ohio listing and likely reflects New York's higher per-trip Medicaid rates. Seller financing at 7% over 24 months is fairly priced given current rates and provides a meaningful de-risking mechanism if contract revenue softens in the transition period.

That's it for Issue #5.

See you next Tuesday.

Will Hamilton, CVA
Founder, Scope Research and HealthFMV

The Weekly Checkup is published every Tuesday morning. Written for general informational purposes. Engagements through Scope Research or HealthFMV require a separate agreement.